The global adult malignant glioma therapeutics market size is expected to Reach US$ 3.1 Bn by 2026 and projected to expand at a CAGR of 9.4% from 2019 to 2026.
This report studies the current as well as future prospects of the global adult malignant glioma therapeutics market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of malignant glioma therapeutics and new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global adult malignant glioma therapeutics market regarding leading segments based on type, therapy, and region.
The global adult malignant glioma therapeutics market has been segmented based on type, therapy, and region. In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others.
The bottom-up approach for determining the market size was studied using various market indicators obtained from secondary sources, which include population in 2018, prevalence of all types of malignant glioma in major countries, variations in therapy cost across major regions, and approval of therapeutics in specific region. The top-down approach was used to derive the market size for therapy segments, wherein revenues of all publicly listed market players were obtained through secondary sources and analyzed for glioma specific revenues by narrowing down to revenue percentage for product segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others. Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2019 to 2026, considering 2018 as the base year.
The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global adult malignant glioma therapeutics market and could influence it in the near future. Market attractiveness analysis has been provided to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global adult malignant glioma therapeutics market. The report also comprises adult malignant glioma disease overview by type, pipeline analysis, Porter’s Five Forces analysis, overview of epidemiology of glioma, snapshot of disease burden by key region / country, SWOT analysis by key therapies, regulatory scenario, reimbursement scenario, comparative analysis of available therapies & imaging landscape, and key market trends by region.
In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2018 as the base year. The report also provides market size and forecast for major countries with each product and distribution channel in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section. This section of the report also provides the market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global adult malignant glioma therapeutics market.
Major players operating in the global adult malignant glioma therapeutics market are Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.
Report Segmentation:
Global Adult Malignant Glioma Therapeutics Market, by Type
Global Adult Malignant Glioma Therapeutics Market, by Therapy
Global Adult Malignant Glioma Therapeutics Market, by Region
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Adult Malignant Glioma Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics by region
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, 2019–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis, by Region
5. Market Outlook
5.1. Adult Malignant Glioma Disease Overview
5.1.1 Glioblastoma Multiforme
5.1.2. Anaplastic Astrocytoma
5.1.3. Anaplastic Oligodendroglioma
5.1.4. Anaplastic Oligoastrocytoma
5.1.5. Others
5.2. Pipeline Analysis
5.2.1. Phase III & IV Drugs Market Forecast
5.2.1. Phase I & II Drug Candidates Comparative Analysis
5.3. Porter’s Five Force Analysis, by Region
5.4. Epidemiology of Glioma
5.4.1. Prevalence, by Country
5.4.2. Prevalence, by Type of Glioma
5.4.3. Incidence Rate, by Country
5.4.4. Incidence Rate, by Type of Glioma
5.5. Disease Burden by Key Regions / Country
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Rest of the World
5.6. SWOT Analysis, by Key Therapies
5.7. Regulatory Scenario, by Key Region / Country
5.8. Reimbursement Scenario, by Key Region / Country
5.9. Imaging Technologies Landscape in Glioma Analysis
5.10. Key Market Trends, by Region
6. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2019– 2026
6.3.1. Glioblastoma Multiforme
6.3.2. Anaplastic Astrocytoma
6.3.3. Anaplastic Oligodendroglioma
6.3.4. Anaplastic Oligoastrocytoma
6.3.5. Others
6.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type
7. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Therapy
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2019–2026
7.3.1. Chemotherapy
7.3.1.1. Temozolomide
7.3.1.2. Bevacizumab
7.3.1.3. Carmustine
7.3.1.4. Others
7.3.2. Targeted Drug Therapy
7.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
7.3.2.2. Other Monoclonal Antibodies
7.3.2.3. Others
7.3.3. Radiation Therapy
7.4. Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy
8. Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Adult Malignant Glioma Therapeutics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2019–2026
9.2.1. Glioblastoma Multiforme
9.2.2. Anaplastic Astrocytoma
9.2.3. Anaplastic Oligodendroglioma
9.2.4. Anaplastic Oligoastrocytoma
9.2.5. Others
9.3. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2019–2026
9.3.1. Chemotherapy
9.3.1.1. Temozolomide
9.3.1.2. Bevacizumab
9.3.1.3. Carmustine
9.3.1.4. Others
9.3.2. Targeted Drug Therapy
9.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
9.3.2.2. Other Monoclonal Antibodies
9.3.2.3. Others
9.3.3. Radiation Therapy
9.4. North America Adult Malignant Glioma Therapeutics Market Value Forecast, by Country, 2019–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Therapy
9.5.3. By Country
10. Europe Adult Malignant Glioma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2019–2026
10.2.1. Glioblastoma Multiforme
10.2.2. Anaplastic Astrocytoma
10.2.3. Anaplastic Oligodendroglioma
10.2.4. Anaplastic Oligoastrocytoma
10.2.5. Others
10.3. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2019–2026
10.3.1. Chemotherapy
10.3.1.1. Temozolomide
10.3.1.2. Bevacizumab
10.3.1.3. Carmustine
10.3.1.4. Others
10.3.2. Targeted Drug Therapy
10.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
10.3.2.2. Other Monoclonal Antibodies
10.3.2.3. Others
10.3.3. Radiation Therapy
10.4. Europe Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Therapy
10.5.3. By Country/Sub-region
11. Asia Pacific Adult Malignant Glioma Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2019–2026
11.2.1. Glioblastoma Multiforme
11.2.2. Anaplastic Astrocytoma
11.2.3. Anaplastic Oligodendroglioma
11.2.4. Anaplastic Oligoastrocytoma
11.2.5. Others
11.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2019–2026
11.3.1. Chemotherapy
11.3.1.1. Temozolomide
11.3.1.2. Bevacizumab
11.3.1.3. Carmustine
11.3.1.4. Others
11.3.2. Targeted Drug Therapy
11.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
11.3.2.2. Other Monoclonal Antibodies
11.3.2.3. Others
11.3.3. Radiation Therapy
11.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Rest of Asia Pacific
11.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Therapy
11.5.3. By Country/Sub-region
12. Latin America Adult Malignant Glioma Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2019–2026
12.2.1. Glioblastoma Multiforme
12.2.2. Anaplastic Astrocytoma
12.2.3. Anaplastic Oligodendroglioma
12.2.4. Anaplastic Oligoastrocytoma
12.2.5. Others
12.3. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2019–2026
12.3.1. Chemotherapy
12.3.1.1. Temozolomide
12.3.1.2. Bevacizumab
12.3.1.3. Carmustine
12.3.1.4. Others
12.3.2. Targeted Drug Therapy
12.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
12.3.2.2. Other Monoclonal Antibodies
12.3.2.3. Others
12.3.3. Radiation Therapy
12.4. Asia Pacific Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Therapy
12.5.3. By Country/Sub-region
13. Middle East & Africa Adult Malignant Glioma Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Type, 2019–2026
13.2.1. Glioblastoma Multiforme
13.2.2. Anaplastic Astrocytoma
13.2.3. Anaplastic Oligodendroglioma
13.2.4. Anaplastic Oligoastrocytoma
13.2.5. Others
13.3. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Therapy, 2019–2026
13.3.1. Chemotherapy
13.3.1.1. Temozolomide
13.3.1.2. Bevacizumab
13.3.1.3. Carmustine
13.3.1.4. Others
13.3.2. Targeted Drug Therapy
13.3.2.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors
13.3.2.2. Other Monoclonal Antibodies
13.3.2.3. Others
13.3.3. Radiation Therapy
13.4. MEA Adult Malignant Glioma Therapeutics Market Value Forecast, by Country/Sub-region, 2019–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. MEA Adult Malignant Glioma Therapeutics Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Therapy
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1.Market Player - Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis, by Company (2018)
14.3.Market Footprint Analysis
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Merck & Co., Inc.
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Strategic Overview
14.5.1.5. Financial Overview
14.5.2. F. Hoffmann-La Roche Ltd.
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Strategic Overview
14.5.2.5. Financial Overview
14.5.3. Arbor Pharmaceuticals
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Strategic Overview
14.5.3.5. Financial Overview
14.5.4. Pfizer, Inc.
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Strategic Overview
14.5.4.5. Financial Overview
14.5.5. AbbVie, Inc.
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Strategic Overview
14.5.5.5. Financial Overview
14.5.6. Amgen, Inc.
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Strategic Overview
14.5.6.5. Financial Overview
14.5.7. Bristol-Myers Squibb Company
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Strategic Overview
14.5.7.5. Financial Overview
14.5.8. Sun Pharmaceuticals Ltd.
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Strategic Overview
14.5.8.5. Financial Overview
14.5.9. Teva Pharmaceutical Industries Limited
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Strategic Overview
14.5.9.5. Financial Overview
14.5.10. Emcure Pharmaceuticals Limited
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Strategic Overview
14.5.10.5. Financial Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers